In the latest trading session,, 2.15 million ImmunityBio Inc (NASDAQ:IBRX) shares changed hands as the company’s beta touched 0.06. With the company’s most recent per share price at $2.70 changed hands at -$0.14 or -4.75% at last look, the market valuation stands at $2.39B. IBRX’s current price is a discount, trading about -198.89% off its 52-week high of $8.07. The share price had its 52-week low at $1.83, which suggests the last value was 32.22% up since then.
Analysts gave the ImmunityBio Inc (IBRX) stock a consensus recommendation rating of Sell, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IBRX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. ImmunityBio Inc’s EPS for the current quarter is expected to be -0.1.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX was in red as seen in intraday trades today. With action 14.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 5.66%, with the 5-day performance at 14.62% in the green. However, in the 30-day time frame, ImmunityBio Inc (NASDAQ:IBRX) is 9.51% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 55.0% from its recent market value. According to analyst projections, IBRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -122.22% plunge from its current level, while the stock would need to soar -122.22% for it to hit the projected low.
ImmunityBio Inc (IBRX) estimates and forecasts
Year-over-year growth is forecast to reach 609.62% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 23.1M. 2 analysts are of the opinion that ImmunityBio Inc’s revenue for the current quarter will be 30.7M. The company’s revenue for the corresponding quarters a year ago was 1.05M and 6.11M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 2,106.30%. The estimates for the next quarter sales put growth at 402.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 2.39%. The 2025 estimates are for ImmunityBio Inc earnings to increase by 26.43%.
IBRX Dividends
ImmunityBio Inc is expected to release its next quarterly earnings report in June.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 1.6629% or 11.42 million shares worth $72.19 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund . With 5.73 shares estimated at $15.54 million under it, the former controlled 0.65% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund held about 0.53% of the shares, roughly 4.65 shares worth around $12.6 million.
